anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Studies in rats and monkeys have shown a substantial difference between doses producing tranquilizing, sedative and toxic effects. In rats, conditioned avoidance response was inhibited at an oral dose of 10 mg/kg; sedation was induced at 32 mg/kg; the LD50 was 1320 mg/kg. In monkeys aggressive behavior was reduced at an oral dose of 0.25 mg/kg; sedation (ataxia) was induced at 7.5 mg/kg; the LD50 could not be determined because of the emetic effect of large doses, but the LD50 exceeds 1600 mg/kg.

Twenty-four dogs were given clorazepate dipotassium orally in a 22-month toxicity study; doses up to 75 mg/kg were given. Drug-related changes occurred in the liver; weight was increased and cholestasis with minimal hepatocellular damage was found, but lobular architecture remained well preserved.

Eighteen rhesus monkeys were given oral doses of clorazepate dipotassium from 3 to 36 mg/kg daily for 52 weeks. All treated animals remained similar to control animals. Although total leucocyte count remained within normal limits it tended to fall in the female animals on the highest doses.

Examination of all organs revealed no alterations attributable to clorazepate dipotassium. There was no damage to liver function or structure.

Reproduction Studies: In fertility studies, clorazepate did not alter the fertility indices or reproductive capacity of adult animals (see Pregnancy).
This method is intended for use in the pharmaceutical industry. It makes it possible to obtain narrowly distributed microcapsules of small sizes, reducing the duration of the process. This method consists of dispersing a mixture of a film-forming polymer solution in highly volatile solvent with the microincapsulable substance in a dispersion of segregation particles in a non-polar liquid. Dispersion is carried out at a temperature higher than the melting point of the segregation particle material. Subsequent formation of segregated particles occurs following the cooling of the mixture to a temperature lower than the melting temperature of the segregation particle material. This is the result of removing the solvent by passing air or inert gas through the mixture, followed by separation of the micro-capsules from the non-polar liquid and of the segregation particles through filtration, rinsing and drying.
FIELD: medicine. SUBSTANCE: hyperimmune serum is adsorbed with the residue of microbial cells obtained from the mixture of two strains of bronchisepticosic microbe with different set of agglutinogens. Adsorption is carried out by hemogenization followed by isolation of the serum which is lyophilly dried in ampoules. For adsorption the strains B.bronchiseptica N 214 and/or N 899 and/or N 5376 are used. The advantage of the present innovation lies in the fact that the serum obtained is of high specificity, high titer in agglutination test being not lower than 1:25 upon a slide and 1: 1280 in agglutination test upon a plotting board. It is a standard dry preparation per 0.1 ml/ampoule at 30% moisture weight, not higher. Expiry date is increased up to 3 years against 1 year for a liquid serum. EFFECT: higher efficiency. 2 cl, 1 ex
This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
The 2016 FAST study brought a "new star" target for gastric cancer - CLDN18.2 (claudin 18 splice variant 2,CLDN18.2), which belongs to the CLDN family of tight junction proteins and is involved in the formation of paracellular tight junctions and maintenance of cell polarity. CLDN18.2 is mainly found in the normal gastric mucosa (normal gastric glands, principal cells, mural cells, endocrine cells) where the differentiation cycle is short and renewal is rapid, and in the duodenal panniculocytes, but not in the gastric stem cell region. It is now generally accepted that CLDN18.2 is expressed in normal gastric tissue confined to the tight junctions at the outer base of the gastric mucosal cells, whereas tumours undergo a change in cell polarity during malignant transformation, resulting in widespread exposure of CLDN18.2 to the cell membrane surface. The CLDN18.2 gene is also aberrantly activated and highly specific and stably expressed in specific tumour tissues, participating in the proliferation, differentiation and migration of tumour cells, making it a potentially effective target for anti-tumour drugs.

In this study, a molecular probe PMD22 targeting CLDN18.2 was synthesised in a previous study and a 68Ga-PMD22 injection was developed for clinical trials. The preliminary study showed that the tracer has good safety and good imaging effect. It is proposed to further conduct exploratory PET/CT imaging studies on patients with gastric cancer, colorectal cancer and other gastrointestinal tumours, to provide a new technique for in vivo, non-invasive and visual detection of CLDN18.2 expression level and spatial distribution for patients with gastric cancer, colorectal cancer and other gastrointestinal tumours, and to validate its clinical application value for the diagnosis of gastric cancer, colorectal cancer and other gastrointestinal tumours.
Remifentanil HCl contains remifentanil, a Schedule II controlled substance. As an opioid, remifentanil HCl exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)]. 

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when handling remifentanil HCl. Strategies to reduce these risks include proper product storage and control practices for a C-II drug. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
The invention discloses non-iodinated radiopaque microbeads that may be used in image guided embolization in a subject ailing with tumor. The non-iodinated radiopaque microbeads include a ceramic material doped with a CT contrast agent or a MRI contrast agent or both. The doped ceramic is blended with a polymer and the blend is electrosprayed to form the radiopaque microbeads. Further the radiopaque microbeads are radiolabeled with a radioactive isotope. Methods of synthesis of the radiopaque microspheres are also disclosed. The non-iodinated radiopaque microbeads with radiolabeling are capable of rendering an imageable computed tomography (CT) contrast or magnetic resonance imaging (MRI) contrast when administered in a subject. Also the microspheres are biodegradable and hence the treatment could be repeated in case of recurrence of the tumor in the subject.
Participants viewed an informational video titled, "All it Takes is 10 Mindful Minutes" by mindfulness expert, Andy Puddicombe. Following the video, a guided discussion was provided that focused on how the principles of mindfulness can be used to influence a physician's state of mental presence, allowing for moments of clarity, insight, and reflection, and potentially enhance provider and patient safety.
Patient decided to start disease modifying treatment, either interferon beta-1a, glatiramer acetate or natalizumab. If interested and consented they would be assigned to Group A. Patient would have blood specimens taken up to 5 times over the next 19 months: Day 0; Day 28; Day 84: Day 336 and Day 508.
The purpose of this study was to verify the efficacy of the ketogenic diet in children with refractory epilepsies followed at a pediatric center in South Vietnam. Patients were considered responders when a 50% seizure frequency was reached.
BACKGROUND: Inflammation is a risk factor for tumorigenesis. Macrophage, a subset of immune cells with high plasticity, plays a multifaceted role in this process. Natural products, which are bioactive compounds derived from traditional herbs or foods, have exhibited diverse effects on macrophages and tumorigenesis making them a valuable resource of drug discovery or optimization in tumor prevention.
PURPOSE: Provide a comprehensive overview of the various roles of macrophages in tumorigenesis, as well as the effects of natural products on tumorigenesis by modulating macrophage function.
METHODS: A thorough literature search spanning the past two decades was carried out using PubMed, Web of Science, Elsevier, and CNKI following the PRISMA guidelines. The search terms employed included "macrophage and tumorigenesis", "natural products, macrophages and tumorigenesis", "traditional Chinese medicine and tumorigenesis", "natural products and macrophage polarization", "macrophage and tumor related microenvironment", "macrophage and tumor signal pathway", "toxicity of natural products" and combinations thereof. Furthermore, certain articles are identified through the tracking of citations from other publications or by accessing the websites of relevant journals. Studies that meet the following criteria are excluded: (1) Articles not written in English or Chinese; (2) Full texts were not available; (3) Duplicate articles and irrelevant studies. The data collected was organized and summarized based on molecular mechanisms or compound structure.
RESULTS: This review elucidates the multifaceted effect of macrophages on tumorigenesis, encompassing process such as inflammation, angiogenesis, and tumor cell invasion by regulating metabolism, non-coding RNA, signal transduction and intercellular crosstalk. Natural products, including vitexin, ovatodiolide, ligustilide, and emodin, as well as herbal remedies, have demonstrated efficacy in modulating macrophage function, thereby attenuating tumorigenesis. These interventions mainly focus on mitigating the initial inflammatory response or modifying the inflammatory environment within the precancerous niche.
CONCLUSIONS: These mechanistic insights of macrophages in tumorigenesis offer valuable ideas for researchers. The identified natural products facilitate the selection of promising candidates for future cancer drug development.
The invention belongs to the technical field of biology, and particularly relates to an antibody for resisting novel coronavirus N protein or an antigen binding fragment thereof and application thereof. The antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises a light chain CDR1 with a sequence shown as SEQ ID NO. 1, a light chain CDR2 with a sequence shown as SEQ ID NO. 2 and a light chain CDR3 with a sequence shown as SEQ ID NO. 3; the heavy chain variable region comprises a light chain CDR1 of the sequence shown in SEQ ID NO. 4, a light chain CDR2 of the sequence shown in SEQ ID NO. 5 and a light chain CDR3 of the sequence shown in SEQ ID NO. 6. The EC50 value of the antibody and the novel coronavirus N protein can reach 16.91ng/ml, namely, the antibody has strong affinity with the novel coronavirus N protein and excellent binding capacity.
A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed for the purification of rHA proteins from A sub-types and B type influenza viruses. The procedure produces substantially pure rHA which is a biologically active hemagglutinin, non-denatured, and suitable as a component in human or other animal influenza vaccines.
OBJECTIVES: A focal intimal disruption (FID) is a risk factor for adverse aorta-related events in patients with acute type B intramural haematoma. This study evaluated the impact of FIDs on overall survival with a selective intervention strategy for large or growing FIDs. Additionally, this study evaluated the risk factors associated with the growth of FIDs.
METHODS: This retrospective study included all consecutive patients admitted for acute type B intramural haematomas between November 2004 and April 2021. The primary outcome was overall survival. The secondary outcome was the cumulative incidence of composite aortic events and the growth of FIDs. The latter was calculated on centreline-reconstructed computed tomography images.
RESULTS: A total of 105 patients were included. A total of 106 FIDs were identified in 73 patients (73/105, 69.5%). The 1- and 5-year cumulative incidence rates of composite aortic events were 36.2% and 39.2%, respectively. The 1- and 5-year overall survival was 93.3% and 81.5%, respectively. Initial maximal aortic diameter and large FIDs during acute phase were significant risk factors for composite aortic events, but not risk factors for overall survival. The early appearance interval of an FID was a significant risk factor for growth of an FID.
CONCLUSIONS: With a selective intervention strategy for large or growing FIDs, the presence of large FIDs during the acute phase does not affect overall survival. The early appearance interval was associated with the growth of FIDs.
Subarachnoid hemorrhage due to the A1 segment of an anterior cerebral artery dissecting aneurysm is rare. Therefore, a standard treatment has not been established. Though several case reports of direct surgery exist, there are few reports on endovascular treatment. This is the first study to describe five patients who underwent endovascular treatment for ruptured A1 dissecting aneurysms. Between January 2001 and December 2022 in our affiliated centers, five cases of SAH-onset A1 dissecting aneurysms were treated with endovascular treatment. We describe in detail two representative cases, briefly summarize the other three, and analyze their complications and outcomes. In the five cases, four were female. Four were in their 50s, and one was in her 80s. The WFNS grades were as follows: three were 2, one was 4, and one was 5. No re-ruptures or symptomatic complications were observed. The modified Rankin Scale scores at the time of discharge were as follows; one was 0, one was 1, two were 2, and one was 5. One in five patients needed retreatment after endovascular trapping because of recanalization. Endovascular treatment may be an effective and viable treatment option for ruptured A1 dissecting aneurysms. Further studies are needed to collect detailed data on complications and outcomes.
A composition for treating cancerous cells in a subject having an immune system includes a virus in the Yatapoxvirus genus having at least one mutation. In one embodiment, the mutation results in suppressed expression of a TNF binding protein by the virus. In another embodiment, the mutation results in suppressed expression of thymidine kinase (“TK”) by the virus. In another embodiment, the mutation arms the virus with a transgene to express a bacterial flagellin. The mutations can be present singly or in combination. Additional aspects include a method of treating cancerous cells with a composition as described herein, and a method of delivering at least one gene to cancerous cells in a subject.
In addition to the conventional physiotherapy program, patients in the intervention group will receive a suprascapular nerve block with musculoskeletal USG guidance available in our clinic at the beginning of rehabilitation. Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.
Abstract Introduction: The surgical extraction of impacted wisdom teeth is a standard practice in dentistry. Unfortunately, inflammatory reactions such as discomfort, edema, and trismus frequently jeopardize patients' well-being after the extraction of third molars. Saline solutions at room temperature (25°C) are routinely used in impacted tooth extraction. Refrigerated serums were used to work with cold serum, and since the refrigerator temperature was 4°C, this study was designed to have a cold serum temperature of 4°C. This study aims to assess the influence of saline irrigation at various temperatures (4°C, 25°C) on postoperative edema, pain, and trismus after the extraction of impacted third molars.

Materials and Methods: Eighteen patients with bilateral symmetrical mandibular impacted third molars were enrolled in this split-mouth, randomized, prospective, double-blind clinical trial. For each patient, one side was irrigated with a solution at 4°C (test), and the other side was irrigated with a solution at room temperature (25°C) (control). Pain, trismus, and facial edema were noted on the 2nd, 4th, and 7th days. A Mann-Whitney U-test was used to compare pairs, and a Wilcoxon signed-rank test was used to compare groups.
PROBLEM TO BE SOLVED: To obtain the subject antimicrobial or microbicidal agent which has excellent antimicrobial and microbicidal activities and is effective for treatment for infectious disease of human and animal by formulating a naphtho[2,3- d]thiazol-4,9-dione derivative thereto. SOLUTION: The objective antimicrobial or micobicidal agent is obtained by formulating a compound (e.g. a compound of formula II) of formula I [R1 is H, an alkyl, a cycloalkyl, -N(R2 )R3 (R2 and R3 are each H, an alkyl, etc.), etc.; X is H, a halogen, nitro, amino and acetylamino; (n) is 1-4] thereto. As the dose of the antimicrobial or microbicidal agent in the usual case of oral administration to adults, the compound of formula I is preferably administrated once to several times a day at a dose of about 10-500 mg.
Traditional hydration assessment methods, while accurate, are often invasive and impractical for routine monitoring. In response, innovative non-invasive techniques such as bioelectrical impedance analysis (BIA), electrodermal activity (EDA), electrocardiogram (ECG) monitoring, and urine color charts have emerged, offering greater comfort and accessibility for patients. These methods use various types of sensors to capture a range of bio-signals, followed by machine learning-based classification or regression methods, providing real-time feedback on hydration status, which is crucial for effective management and prevention of urinary stones. This review explores the principles, applications, and efficacy of these non-invasive techniques, highlighting their potential to transform hydration monitoring in clinical and everyday settings. By facilitating improved patient compliance and enabling proactive hydration management, these approaches align with contemporary trends in personalized healthcare. This article presents a literature review on non-invasive approaches to hydration assessment, focusing on their significance in preventing kidney stone disease and enhancing kidney health.
Acute myocardial infarction is a significant health issue, particularly in Jordan where ischemic heart disease is the leading cause of death. Effective management of acute myocardial infarction is essential to mitigate its consequences. Although health literacy is crucial for the successful management of acute myocardial infarction, research about the strengths and needs of health literacy among acute myocardial infarction patients is still limited. This study was conducted to identify the health literacy strengths and needs of Jordanian acute myocardial infarction patients using cluster analysis. A cross-sectional design was used to conduct this study in a sample of acute myocardial infarction patients in Jordan (N = 114). A demographics questionnaire and the Health Literacy Questionnaire were used to collect the data. Data analysis was performed using hierarchical cluster analysis using Ward's method. Seven distinct clusters of acute myocardial infarction patients were identified, each characterized by unique health literacy profiles and sociodemographic characteristics. Cluster 7 had the highest health literacy scores across all nine Health Literacy Questionnaire scales. Sociodemographic factors such as age, education level, and gender influenced health literacy levels, with female, younger, more educated patients exhibiting higher health literacy. Through identifying the specific strengths and needs, this research provides a foundation for developing targeted health literacy interventions for acute myocardial infarction patients. Improving health literacy among acute myocardial infarction patients can enhance their ability to manage their health and potentially reduce the complications associated with acute myocardial infarction.
Ferric Sulfate (FS), widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The FS solution was kept in the cavity for 15 seconds using cotton pellets in the FS group.
Placebo will be administered orally at the same number of capsules as active drug at each Cohort. Placebo capsules will consist of inactive ingredients and look identical to BTRX-246040.
BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe long-term complication of acute pulmonary embolism (PE). We aimed to evaluate the impact of a symptom screening programme to detect CTEPH in PE survivors.
METHODS: This was a multicentre cohort study of patients diagnosed with acute symptomatic PE between January 2017 and December 2018 in 16 centres in Spain. Patients were contacted by phone 2 years after the index PE diagnosis. Those with dyspnoea corresponding to a New York Heart Association (NYHA)/WHO scale≥II, visited the outpatient clinic for echocardiography and further diagnostic tests including right heart catheterisation (RHC). The primary outcome was the new diagnosis of CTEPH confirmed by RHC.
RESULTS: Out of 1077 patients with acute PE, 646 were included in the symptom screening. At 2 years, 21.8% (n=141) reported dyspnoea NYHA/WHO scale≥II. Before symptom screening protocol, five patients were diagnosed with CTEPH following routine care. In patients with NYHA/WHO scale≥II, after symptom screening protocol, the echocardiographic probability of pulmonary hypertension (PH) was low, intermediate and high in 76.6% (n=95), 21.8% (n=27) and 1.6% (n=2), respectively. After performing additional diagnostic test in the latter 2 groups, 12 additional CTEPH cases were confirmed.
CONCLUSIONS: The implementation of this simple strategy based on symptom evaluation by phone diagnosed more than doubled the number of CTEPH cases. Dedicated follow-up algorithms for PE survivors help diagnosing CTEPH earlier.
TRIAL REGISTRATION NUMBER: NCT03953560.